Krystal Biotech’s (KRYS) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Krystal Biotech (NASDAQ:KRYS) in a research report sent to investors on Wednesday morning,Benzinga reports. The firm currently has a $221.00 target price on the stock.

Several other brokerages have also issued reports on KRYS. Citigroup raised their target price on Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Chardan Capital restated a “buy” rating and set a $212.00 price objective on shares of Krystal Biotech in a report on Thursday, December 12th. William Blair upgraded shares of Krystal Biotech to a “strong-buy” rating in a research note on Friday, August 30th. Cantor Fitzgerald restated an “overweight” rating on shares of Krystal Biotech in a research note on Thursday, August 29th. Finally, Stifel Nicolaus lifted their price target on shares of Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a report on Wednesday, September 11th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Krystal Biotech currently has an average rating of “Buy” and a consensus price target of $206.67.

Krystal Biotech Stock Performance

Krystal Biotech stock opened at $164.83 on Wednesday. Krystal Biotech has a fifty-two week low of $107.50 and a fifty-two week high of $219.34. The firm’s 50-day simple moving average is $180.18 and its 200 day simple moving average is $185.00. The stock has a market cap of $4.74 billion, a PE ratio of 93.12 and a beta of 0.80.

Krystal Biotech (NASDAQ:KRYS) last announced its earnings results on Monday, November 4th. The company reported $0.91 earnings per share for the quarter, topping analysts’ consensus estimates of $0.84 by $0.07. The firm had revenue of $83.84 million for the quarter, compared to the consensus estimate of $82.94 million. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The company’s revenue was up 879.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.67) EPS. As a group, analysts predict that Krystal Biotech will post 2.97 EPS for the current fiscal year.

Insider Activity

In related news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $164.78, for a total value of $4,119,500.00. Following the completion of the transaction, the insider now directly owns 1,475,882 shares in the company, valued at approximately $243,195,835.96. The trade was a 1.67 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 14.10% of the company’s stock.

Hedge Funds Weigh In On Krystal Biotech

A number of large investors have recently made changes to their positions in the stock. EFG Asset Management North America Corp. raised its stake in shares of Krystal Biotech by 0.5% during the 2nd quarter. EFG Asset Management North America Corp. now owns 12,555 shares of the company’s stock valued at $2,308,000 after purchasing an additional 60 shares during the period. Nisa Investment Advisors LLC increased its position in shares of Krystal Biotech by 11.1% during the second quarter. Nisa Investment Advisors LLC now owns 940 shares of the company’s stock valued at $173,000 after buying an additional 94 shares during the period. Arizona State Retirement System lifted its holdings in shares of Krystal Biotech by 2.1% in the second quarter. Arizona State Retirement System now owns 5,147 shares of the company’s stock worth $945,000 after buying an additional 108 shares in the last quarter. Fiera Capital Corp boosted its position in shares of Krystal Biotech by 0.8% in the second quarter. Fiera Capital Corp now owns 16,208 shares of the company’s stock valued at $2,976,000 after acquiring an additional 130 shares during the period. Finally, KBC Group NV grew its stake in Krystal Biotech by 25.9% during the third quarter. KBC Group NV now owns 642 shares of the company’s stock valued at $117,000 after acquiring an additional 132 shares in the last quarter. 86.29% of the stock is owned by institutional investors.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).